Q3 2025 13F Holders as of 30 Sep 2025
-
Type / Class
-
Equity / Common stock, par value $0.0001 per share
-
Shares outstanding
-
7,179,487
-
Total 13F shares
-
211,031
-
Share change
-
+211,031
-
Total reported value
-
$320,773
-
Price per share
-
$1.52
-
Number of holders
-
21
-
Value change
-
+$320,773
-
Number of buys
-
21
Institutional Holders of Calidi Biotherapeutics, Inc. - Common stock, par value $0.0001 per share (CLDI) as of Q3 2025
As of 30 Sep 2025,
Calidi Biotherapeutics, Inc. - Common stock, par value $0.0001 per share (CLDI) was held by
21 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
211,031 shares.
The largest 10 holders included
HighTower Advisors, LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, Belpointe Asset Management LLC, Warberg Asset Management LLC, RS CRUM INC., UBS Group AG, Finepoint Capital LP, Apollo Management Holdings, L.P., and HIGHBRIDGE CAPITAL MANAGEMENT LLC.
This page lists
21
institutional shareholders reporting positions in this security
for the Q3 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.